Knowledge, acceptance and perception about COVID-19 vaccines in Bangladesh: Findings from a web-based cross-sectional study

Hossain, Md. Sakhawat; Islam, Md. Rabiul; Islam, Md. Ariful; Islam, Romana; Khan, Md. Robin; Saha, Tushar; Hossain, Moazzem; Bhuiyan, Mohiuddin Ahmed

doi:10.1515/openhe-2022-0010

Cited by 6 publications

(5 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The virus has quickly spread across Bangladesh from March 2020 to October 2022, and the number of confirmed cases reportedly has risen to 2 million, with 29,430 deaths 3 . To combat COVID‐19, the Government of the People's Republic of Bangladesh has fully approved seven COVID‐19 vaccines, such as AstraZeneca, Pfizer, Sinopharm, Moderna, Sinovac, Janssen (Johnson & Johnson), Pfizer‐PF (Comirnaty) 7,8 . In Bangladesh, vaccine against corona virus was initiated in January 2021 to the frontline health workers while mass vaccination started on February 7, 2021 9 .…”

Section: Introductionmentioning

confidence: 99%

“…3 To combat COVID‐19, the Government of the People's Republic of Bangladesh has fully approved seven COVID‐19 vaccines, such as AstraZeneca, Pfizer, Sinopharm, Moderna, Sinovac, Janssen (Johnson & Johnson), Pfizer‐PF (Comirnaty). 7 , 8 In Bangladesh, vaccine against corona virus was initiated in January 2021 to the frontline health workers while mass vaccination started on February 7, 2021. 9 As of October 6, 2022, a total of 12.749 billion doses have been administered globally whereas more than 298 million doses have been administered in Bangladesh ( https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/ ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Temporal dynamics and fatality of SARS‐CoV‐2 variants in Bangladesh

Rahman¹,

Hoque

Chowdhury³

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Background and Aims: Since the beginning of the SARS-CoV-2 pandemic, multiple new variants have emerged posing an increased risk to global public health. This study aimed to investigate SARS-CoV-2 variants, their temporal dynamics, infection rate (IFR) and case fatality rate (CFR) in Bangladesh by analyzing the published genomes. Methods: We retrieved 6610 complete whole genome sequences of the SARS-CoV-2 from the GISAID (Global Initiative on Sharing all Influenza Data) platform from March 2020 to October 2022, and performed different in-silico bioinformatics analyses. The clade and Pango lineages were assigned by using Nextclade v2.8.1. SARS-CoV-2 infections and fatality data were collected from the Institute of Epidemiology Disease Control and Research (IEDCR), Bangladesh. The average IFR was calculated from the monthly COVID-19 cases and population size while average CFR was calculated from the number of monthly deaths and number of confirmed COVID-19 cases.Results: SARS-CoV-2 first emerged in Bangladesh on March 3, 2020 and created three pandemic waves so far. The phylogenetic analysis revealed multiple introductions of SARS-CoV-2 variant(s) into Bangladesh with at least 22 Nextstrain clades and 107 Pangolin lineages with respect to the SARS-CoV-2 reference genome of Wuhan/Hu-1/2019. The Delta variant was detected as the most predominant (48.06%) variant followed by Omicron (27.88%), Beta (7.65%), Alpha (1.56%), Eta (0.33%) and Gamma (0.03%) variant. The overall IFR and CFR from circulating variants were 13.59% and 1.45%, respectively. A time-dependent monthly analysis showed significant variations in the IFR (p = 0.012, Kruskal-Wallis test) and CFR (p = 0.032, Kruskal-Wallis test) throughout the study period. We found the highest IFR (14.35%) in 2020 while Delta (20A) and Beta (20H) variants were circulating in

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Temporal dynamics and fatality of SARS‐CoV‐2 variants in Bangladesh

Rahman¹,

Hoque

Chowdhury³

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…The healthcare systems around the globe are fighting critical challenges associated with this disease 2–4 . We have observed the tremendous impact on the mental health of people in Asian countries due to the effects of Covid‐19 that are reflected in different studies 5–12 . A study measured anxiety and depressive symptoms among healthcare professionals from India, China, Malaysia, and other south Asian countries 13 .…”

Section: Introductionmentioning

confidence: 99%

Prevalence and associated factors for elevated fear and depressive symptoms among the private service holders in Bangladesh during the Covid‐19 pandemic: A cross‐sectional study

Islam

Nahar

Hossain

et al. 2022

Health Science Reports

Self Cite

View full text Add to dashboard Cite

Background and Aims: The ongoing public health emergency has created incredible fear of getting the infection and a terrible psychological burden among all levels. The pandemic has severely affected private job holders' economic status and lifestyle factors in Bangladesh. Here we aimed to assess fear and depressive symptoms among private job holders in Bangladesh during the Covid-19 pandemic and associated risk factors. Methods:We conducted this online cross-sectional survey between January 15, 2021, and March 15, 2021, among 510 private job holders aged above 18 years. We followed the convenience sampling method for data collection. We assessed sociodemographic factors and two psychometric parameters. We applied the Fear of Covid-19 Scale and Patient Health Questionnaire-9 to assess increased fear and depressive symptoms, respectively. Chi-square test, independent sample t-test, and binary logistic regression analysis were performed for data analysis. Results:The prevalence of increased fear and depressive symptoms were 86.27% and 42.16%, respectively. Factors associated with increased fear among private job holders during COVID-19 were economic class, obesity, on-time salary, company's downsizing policy, salary reduction, home office, and transportation facilities.However, depressive symptoms were associated with marital status, education level, residence area, the organizational practice of health safety rules, company performance, on-time salary, health insurance, downsizing, salary reduction policy, organization type, transportation, and mental health support at work. The present study also noticed some interrelations among the above factors with mental health issues.

show abstract

“… 8 - 10 This heavily mutated variant is rapidly spreading around the world that is of great health concern. 11 - 13 The World Health Organization (WHO) designated this SARS-CoV-2 variant as the variant of concern (VOC) on November 26, 2021. 14 Since January 2021, the arrival of the subsequent Alpha (α), Beta (β), and Delta (δ) in association with new waves of infections, SARS-CoV-2 VOCs became dominant across the entire world in many countries.…”

Section: Introductionmentioning

confidence: 99%

Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health

Islam

Nasreen

Anjum

et al. 2022

Clin Med�Insights�Pathol

View full text Add to dashboard Cite

The discovery of the SARS-CoV-2 Omicron (B.1.1.529) variant has sparked alarm globally because of its rapid rate of infection and trespassing acquired immunity due to vaccination or natural infection. This heavily mutated variant is rapidly spreading around the world. Infected individuals with the Omicron variant may suffer from flu-like symptoms, and infected with the Delta variant frequently report low oxygen levels, high pulse rates, and a loss of smell and taste. Also, the Omicron variant causes asymptomatic or mild disease so far, and not any severe illness as like Delta, and this new variant has a 15% to 80% reduced risk of hospitalization than the Delta variant. Scientists are worried about the possibility of escaping the immunity by the Omicron variants and subvariants among fully vaccinated and recovered COVID-19 patients. Two doses of available vaccines are found to be partially ineffective in protecting this new variant, therefore, the third dose as a booster is recommended to enhance antibody level. Moreover, some antiviral drugs significantly reduce hospitalization or death among mild to severe COVID-19 patients. All authorized antiviral drugs are effective against viral replication for most SARS-CoV-2 variants, and particularly some monoclonal antibodies may not now be effective in treating COVID-19 patients. There is an urgent need to update existing vaccines, develop more effective and newer vaccines as well as additional monoclonal antibodies to counter Omicron. Therefore, along with close monitoring of Omicron characteristics, the present study suggests that health safety guidelines, mass immunization, early diagnosis, and search for effective antiviral drugs should be the approaches to fight against newer SARS-CoV-2 variants.

show abstract

Knowledge, acceptance and perception about COVID-19 vaccines in Bangladesh: Findings from a web-based cross-sectional study

Cited by 6 publications

References 51 publications

Temporal dynamics and fatality of SARS‐CoV‐2 variants in Bangladesh

Temporal dynamics and fatality of SARS‐CoV‐2 variants in Bangladesh

Prevalence and associated factors for elevated fear and depressive symptoms among the private service holders in Bangladesh during the Covid‐19 pandemic: A cross‐sectional study

Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health

Contact Info

Product

Resources

About